GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Debt-to-Asset

RDHL (Redhill Biopharma) Debt-to-Asset : 0.03 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Debt-to-Asset?

Redhill Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.37 Mil. Redhill Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.19 Mil. Redhill Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $22.02 Mil. Redhill Biopharma's debt to asset for the quarter that ended in Jun. 2024 was 0.03.


Redhill Biopharma Debt-to-Asset Historical Data

The historical data trend for Redhill Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Debt-to-Asset Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.48 0.49 0.77 0.05

Redhill Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.12 0.07 0.05 0.03

Competitive Comparison of Redhill Biopharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Debt-to-Asset falls into.



Redhill Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Redhill Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Redhill Biopharma's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (NAS:RDHL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Redhill Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma Business Description

Traded in Other Exchanges
N/A
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.